S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
NASDAQ:MNOV

MediciNova - MNOV Stock Forecast, Price & News

$2.48
-0.01 (-0.40%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.41
$2.48
50-Day Range
$2.28
$2.62
52-Week Range
$2.09
$4.65
Volume
27,218 shs
Average Volume
60,616 shs
Market Capitalization
$121.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

MediciNova MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
141.9% Upside
$6.00 Price Target
Short Interest
Bearish
2.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.22mentions of MediciNova in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.21) to ($0.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

844th out of 1,125 stocks

Pharmaceutical Preparations Industry

428th out of 554 stocks

MNOV stock logo

About MediciNova (NASDAQ:MNOV) Stock

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

MediciNova Stock Up 2.0 %

MNOV opened at $2.49 on Monday. MediciNova has a twelve month low of $2.09 and a twelve month high of $4.65. The company has a 50-day simple moving average of $2.46 and a 200 day simple moving average of $2.52.

MediciNova (NASDAQ:MNOV - Get Rating) last announced its quarterly earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.02. Sell-side analysts anticipate that MediciNova will post -0.21 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of MediciNova in a research report on Friday. They issued a "hold" rating on the stock.

Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Stock News Headlines

MediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.com
See More Headlines
Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Company Calendar

Last Earnings
10/26/2020
Today
8/15/2022
Next Earnings (Estimated)
11/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MNOV
Employees
11
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+141.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-10,130,000.00
Pretax Margin
-33,961.38%

Debt

Sales & Book Value

Annual Sales
$4.04 million
Book Value
$1.71 per share

Miscellaneous

Free Float
41,297,000
Market Cap
$121.63 million
Optionable
Optionable
Beta
0.97

Social Links


Key Executives

  • Dr. Yuichi Iwaki M.D. (Age 72)
    Ph.D., Co-Founder, Pres, CEO & Exec. Director
    Comp: $777.7k
  • Dr. Kazuko Matsuda M.D. (Age 56)
    M.P.H., MPH, Ph.D., Chief Medical Officer & Director
    Comp: $564.13k
  • Mr. Jason J. Kruger CPA (Age 45)
    CFO & Principal Financial Officer
  • Dr. David H. Crean M.B.A. (Age 57)
    Ph.D., Chief Bus. Officer
  • Mr. John O'Neil CPA
    Controller













MNOV Stock - Frequently Asked Questions

Should I buy or sell MediciNova stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MNOV shares.
View MNOV analyst ratings
or view top-rated stocks.

What is MediciNova's stock price forecast for 2022?

1 brokers have issued 1 year price objectives for MediciNova's shares. Their MNOV share price forecasts range from $6.00 to $6.00. On average, they predict the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 141.9% from the stock's current price.
View analysts price targets for MNOV
or view top-rated stocks among Wall Street analysts.

How have MNOV shares performed in 2022?

MediciNova's stock was trading at $2.68 at the beginning of the year. Since then, MNOV shares have decreased by 7.5% and is now trading at $2.48.
View the best growth stocks for 2022 here
.

When is MediciNova's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our MNOV earnings forecast
.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) released its quarterly earnings results on Monday, October, 26th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.04.

What other stocks do shareholders of MediciNova own?
What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

Who are MediciNova's major shareholders?

MediciNova's stock is owned by a variety of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.73%), JPMorgan Chase & Co. (0.60%), UBS Group AG (0.38%), Renaissance Technologies LLC (0.33%), Bailard Inc. (0.04%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Hideki Nagao, Kazuko Matsuda and Yuichi Iwaki.
View institutional ownership trends
.

How do I buy shares of MediciNova?

Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $2.48.

How much money does MediciNova make?

MediciNova (NASDAQ:MNOV) has a market capitalization of $121.63 million and generates $4.04 million in revenue each year.

When was MediciNova founded?

MediciNova was founded in 2000.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The official website for the company is medicinova.com. The biopharmaceutical company can be reached via phone at (858) 373-1500, via email at info@medicinova.com, or via fax at 858-404-0048.

This page (NASDAQ:MNOV) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.